How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen

Jun 09, 2016, 08:00 ET from Chelmsford Park SA

NEW YORK, June 9, 2016 /PRNewswire/ --

Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:

On Wednesday, shares in Boulder, Colorado headquartered biopharmaceutical Company; Clovis Oncology Inc. recorded a trading volume of 828,578 shares. The stock ended the day at $15.87, which was a correction of 3.17%. The Company's shares have gained 15.50% in the last one month. The stock is trading above its 50-day moving average by 4.34%. Furthermore, shares of Clovis Oncology have a Relative Strength Index (RSI) of 53.47. Sign up and activate your free alert on CLVS at:

San Diego, California-based sequencing and array-based solutions provider for genetic analysis, Illumina Inc.'s stock finished yesterday's session 0.21% higher at $145.26 and with a total volume of 627,689 shares traded. The Company's shares have gained 2.47% in the last one month. The stock is trading below its 50-day moving average by 2.52%. Furthermore, shares of Illumina have an RSI of 47.98. Register for free on and activate your trade alert on ILMN at:

At the closing bell on Wednesday, shares in NewLink Genetics Corp., a biopharmaceutical Company which focuses on discovering, developing, and commercializing immunotherapeutic products, surged 5.76%, ending the day at $12.30. The stock recorded a trading volume of 594,292 shares. The Company's shares are trading 18.03% below their 50-day moving average. Moreover, NewLink Genetics' stock has an RSI of 47.91. Register for free on and access the latest research on NLNK at:

Boston, Massachusetts-based biopharmaceutical Company, Zafgen Inc.'s stock ended the day flat at $6.77 and with a total volume of 472,858 shares traded. The Company's shares have gained 6.28% in the last month, 5.12% over the previous three months, and 7.63% on an YTD basis. The stock is trading 0.43% above its 50-day moving average. Additionally, shares of Zafgen, which focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders, have an RSI of 50.30. ZFGN free trade alert is just a click away at:

Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA